A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone

NCT00457392 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

960

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small Cell Lung

Interventions

DRUG: erlotinib
DRUG: sunitinib
DRUG: erlotinib
DRUG: placebo

Sponsor

Pfizer